These findings suggest that 1,25(OH)2D3 may influence sorafenib resistance in hepatocellular carcinoma by modulating the FOXO3A/FOXM1 axis, indicating that targeting FOXO3A and FOXM1 could be a promising molecular therapeutic strategy. The gene discussed is FOXM1; the disease is hepatocellular carcinoma.